Pfizer is Backing This Micro-cap Stock

Sponsored by

Good day, 360 –

Here are our top 3 trade ideas today – these setups look primed!

And a special invitation to join HERE for a 1pm ETexplosive penny stock trading session with Jason Bond in Lightning Alerts⚡. Learn the exact steps he used to spot AMAM at $.56 before it shot up 1000% the same day! And at 7pm ET he’ll be doubling down HERE on his top 3 catalysts for swing trading penny stocks – don’t miss it

ORIC - Over 50% higher in pre-market after reporting a clinical development collaboration with Pfizer and $25 million equity investment from Pfizer

ENPH - Piper Sandler maintains overweight on Enphase Energy, raises price target to $350

GROM - Low float up over 40% on no news

ORIC - Over 50% higher in pre-market after reporting a clinical development collaboration with Pfizer and $25 million equity investment from Pfizer

ORIC Pharmaceuticals reported it would collaborate with Pfizer for ORIC-533 in Multiple Myeloma. It would also offer 5.38 million shares of common stock directly to Pfizer at $4.65/share. That represents a premium of over 50% to the last closing price of $3 for ORIC.

$4.65/sh is the purchase price from Pfizer and this may be an important pivot point today.

Above it, there is potential resistance at $5 and the $5.50 area.

Below $4.65 there is potential support at $4.40 and then $4.10. $4 is an important psychological level and there is a gap to fill to $3 below that.

ENPH - Piper Sandler maintains overweight on Enphase Energy, raises price target to $350  

ENPH has been one of the hottest stocks in the hottest sector this year. The Solar energy company’s stock is up over 150% this year, and despite the recent market pullback it is still only around 6-7% off all-time highs. It has been consolidating at these levels for quite a while so this price target increase could be the catalyst to send it higher.

$315 was prior support and could be an important pivot level.

Above it, targets to the upside are $320, $325, $330 and then all-time highs around $340.

Below $315, there is potential support at $310, $304 and then the psychologically important $300 level.

GROM - Low float up over 40% on no news

Grom Social Enterprises is a low float stock with less than 2 million shares in the float according to Finviz. The company had a 1 for 30 reverse split on Dec 9th, 2022. It’s been trading in a tight consolidation since the reverse split and perhaps someone has been accumulating the stock over the past couple of weeks.

$1.91-$1.94 was a support area in the pre-market.

Above it there is a major resistance level at the $2.30 area which is the pre-market high. Above that there is a gap to fill at $3.86 with potential resistance at $3 which was prior support.

Below $1.91 there is potential support at $1.70 and below that there is a gap to fill at yesterday’s close of $1.51.

Economic Calendar Thursday

GDP 8:30am ET

Jobless Claims 8:30am ET

Chicago Fed Activity Index 8:30am ET

Corporate Profits 8:30am ET

Leading Indicators 10:00am ET

EIA Natural Gas Report 10:30am ET

KC Fed Mfg Index 11:00am ET

Earnings for Thursday

After Market:

AVO, LMNR

META GOOG Tech Giants Ditch Office Space In London And Europe – FT

TSLA Tesla Sends Shanghai Boss and Aides to Jumpstart US Output Reuters

COSM Successful Closing of $32.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market

GD General Dynamics Electric Boat Awarded $5.1 Billion by U.S. Navy for Columbia-Class Submarines

MRNA Moderna Finalizes Strategic Partnership with UK Government Yahoo

MRK Merck and Kelun-Biotech Announce Exclusive License and Collaboration Agreement for Seven Investigational Antibody-drug Conjugate Candidates for the Treatment of Cancer

TSN Hundreds of Tyson Foods Staff Leaving the Company, Including Senior Managers WSJ

BBIO: BridgeBio Pharma Initiates CALIBRATE, A Pivotal Phase 3 Study of Encaleret in Autosomal Dominant Hypocalcemia Type 1

KMX Carmax Pauses Share Buyback After Quarterly Profit Plunges 86% Nasdaq.com

VORB: Virgin Orbit Receives U.K.’s First Orbital Launch License; All LauncherOne Systems Green for Upcoming Mission

INMB: INmune Bio, Inc., Virginia Commonwealth University, and Barrow Neurological Institute Receive Department of Defense Funding to Study the Role of Traumatic Brain Injury in the Development of Alzheimer’s Disease

GOOG GOOGL stock target slashed at Needham on a weaker ad spending outlook in 2023

RIGL Rigel Announces Availability of REZLIDHIA™ (olutasidenib) in the U.S. for the Treatment of Adult Patients with Relapsed or Refractory Acute Myeloid Leukemia with a Susceptible IDH1 Mutation

COMS: COMSovereign Announces the Sale of Its Sky Sapience Drone Subsidiary

To Your Success!

62 Calef Hwy #233 Lee, New Hampshire 03861 United States

Questions or concerns about our products? Email [email protected] © Copyright 2022, RagingBull - Refund Policy - Privacy Policy - Terms & Conditions